Nabriva buys Zavante Therapeutics and its late-stage antibiotic drug


Nabriva Therapeutics, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, announced that it has acquired Zavante Therapeutics (USA), a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.

Nabriva Therapeutics, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics.

CONTEPO (fosfomycin for injection, previously referred to as ZTI-01 and ZOLYD), is Zavante Therapeutics’ novel, potentially first-in-class in the United States, intravenous investigational antibiotic. CONTEPO is in development to treat serious infections, including those caused by multi-drug resistant Gram-negative and Gram-positive bacteria.

Lefamulin is a semi-synthetic pleuromutilin discovered and developed by the Nabriva Therapeutics team. It is designed to inhibit the synthesis of bacterial protein, which is required for bacteria to grow. Lefamulin’s binding occurs with high affinity, high specificity and at molecular sites that are different than other antibiotic classes. Nabriva Therapeutics has completed two pivotal Phase 3 trials evaluating the safety and efficacy of lefamulin for the treatment of adults with community-acquired bacterial pneumonia (CABP). In both studies, lefamulin met all primary and secondary endpoints and was shown to be generally well tolerated. As a result of the favorable safety and tolerability profile observed in clinical trials to date, Nabriva Therapeutics believes lefamulin represents a potentially important new treatment option.